SAM
CRSP icon

Silvercrest Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Silvercrest Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,576
Closed -$448K – 914
2024
Q1 		$448K Hold
6,576
– – ﹤0.01% 728
2023
Q4 		$412K Buy
+6,576
New +$364K ﹤0.01% 703

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Silvercrest Asset Management's CRSP Position: Q2 2024 in Review

Silvercrest Asset Management sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 6,576 shares — an estimated $448K sold.

Silvercrest Asset Management first reported a position in CRSP in Q4 2023 and held it in 2 quarters. The position peaked at $448K in Q1 2024. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Silvercrest Asset Management reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Silvercrest Asset Management sold 6,576 CRISPR Therapeutics shares in Q2 2024, an estimated $448K.
  • Silvercrest Asset Management first reported a position in CRISPR Therapeutics in Q4 2023 and held it in 2 quarters.
  • Silvercrest Asset Management's CRISPR Therapeutics position peaked at $448K in Q1 2024.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Silvercrest Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.